By contrast, the antiphosphaturic effects of rhGH-treatment in children with inherited renal hypophosphatemia, i.e., X-linked hypophosphatemic rickets, were only transient, indicating the importance of other phosphaturic hormones, i.e., fibroblast growth factor 23, in this particular disease [50]
BREAKING NEWS APRIL 15, 2026 - In a welcome announcement to the SSRP community, the FDA reported today that it will imminently remove the following bulk drug substances from category 2: BPC-157, LL-37, DiHexa, DSIP, Epitalon, *GHK-Cu (injectable only), KPV, PEG-MGF, Melanotan II, MOTs-C, Semax, and TB-500
For "GHK-Cu vs NAD+: Which Is Better?", the useful question is not just what the page says, but what a reader should confirm afterward
doi:10.1023/A:1006849713407